SSRI Land of Opportunity

The most widely-used antidepressants in China by the end of last year were GlaxoSmithKline’s Paxil/Seroxat (paroxetine) with a value market share of 18%, followed by Pfizer’s Zoloft (sertraline; 10%) and Eli Lilly’s Prozac (fluoxetine; also 10%). Lundbeck’s older drug Cipramil (citalopram), also sold by Xian-Janssen, and Lexapro had market shares of 6.5% and 3.0% respectively.

http://www.pharmatimes.com/Article/10-12-16/Lundbeck_sees_China_as_land_of_opportunity_for_Lexapro.aspx